Hair Loss and High Blood Pressure: Is Balding a Sign of Heart Disease?

How Are Hair Loss and Heart Health Connected?

Androgenetic alopecia (AGA) is the medical name for male pattern baldness and female pattern hair loss. It affects about 85% of men and 40% of women over the course of their lives.

Over the past two decades, research has found a pattern. People with AGA, especially those who develop it early, tend to have a less favourable cardiovascular risk profile than people of the same age without hair loss.

A 2013 meta-analysis in BMJ Open pooled data from six observational studies covering nearly 37,000 men. It reported that men with vertex, or crown, baldness had a statistically significant increase in the odds of coronary heart disease, compared with men who kept their hair. The association was stronger with more severe baldness, and was significant in younger men as well as across all participants.

A 2010 study in the Journal of the American Academy of Dermatology compared men and women with AGA to matched controls. It found higher rates of high blood pressure, abnormal cholesterol, and central obesity in the AGA group.

More recent work supports these findings. A 2022 review in Dermatology and Therapy concluded that AGA is associated with several cardiometabolic conditions, including hypertension, insulin resistance, abnormal cholesterol, and metabolic syndrome. A 2024 scoping review in PLOS One reached similar conclusions for early-onset AGA, starting before age 40.

It is important to note that these findings describe an association, not causation. Hair loss does not cause heart disease, and having AGA does not mean a person will develop cardiovascular problems.

The link is statistical. It shows up when large groups of people are studied. In practice, it means that patients with early or significant AGA may benefit from routine cardiovascular screening, in the same way any other risk factor would lead to a review.

Why Is Pattern Baldness at the Crown Particularly Associated with Cardiac Risk?

Not all hair loss patterns carry the same cardiovascular signal. The strongest links in the research relate to vertex baldness, which is thinning at the crown of the head. A receding hairline alone shows a weaker link.

Several studies involving Asian men are useful for a Singapore context:

• A 2021 cross-sectional study in Han Chinese men, published in the International Journal of General Medicine, found a link between androgenic alopecia and coronary artery disease.
• A 2017 study in Cardiovascular Endocrinology identified androgenic alopecia, premature greying, and hair thinning as independent predictors of coronary artery disease in young Asian males.

Researchers are still investigating why crown baldness in particular may signal cardiovascular risk. The leading theory points to the density of androgen receptors in follicles at the crown, and the body-wide hormonal environment that drives hair miniaturisation, which is the gradual shrinking of hair follicles in that area.

What Is the Role of DHT and Androgens in Both Conditions?

Androgens are male-type hormones. The most relevant one for hair loss is dihydrotestosterone (DHT), which is a more potent form of testosterone.

An enzyme in the body called 5-alpha-reductase converts testosterone into DHT. In hair follicles that are genetically sensitive to DHT, this causes miniaturisation: hairs become progressively finer, shorter, and lighter in colour, until the follicle produces no visible hair.

Androgens also act on the cardiovascular system. Cells in the heart and blood vessels have receptors for androgens, and changes in androgen signalling have been linked to cardiovascular risk.

Studies have reported associations between early-onset AGA and markers such as insulin resistance, abnormal cholesterol profiles, and high blood pressure. This suggests that shared hormonal pathways may contribute to both hair follicle miniaturisation and cardiometabolic changes.

This shared biology helps explain why the two conditions occur together more often than chance would predict. It does not mean one causes the other directly.

Can High Blood Pressure Itself Cause Hair Loss?

A 2007 study in the European Journal of Dermatology evaluated 250 Caucasian men aged 35 to 65. It found that hypertension was strongly and independently associated with androgenetic alopecia, with an odds ratio of about 2.2.

The authors proposed that aldosterone, a hormone that is often raised in high blood pressure, may play a role. They noted that spironolactone, an aldosterone blocker used to treat high blood pressure, has long been used off-label in the treatment of female pattern hair loss.

A separate theory focuses on the small blood vessels that supply the scalp. Long-term high blood pressure can contribute to stiff arteries and reduced blood flow in small vessels. Both may lower the delivery of oxygen and nutrients to hair follicles.

A 2014 study used a measure called the cardio-ankle vascular index. It found increased arterial stiffness in otherwise healthy young men with AGA, suggesting vascular changes may be present early in the disease process.

Not all studies agree. A 2020 case-control study of 256 men with AGA and 256 matched controls found no significant difference in systolic or diastolic blood pressure between the two groups.

The current scientific view, reflected in recent reviews, is that the link between AGA and high blood pressure is real but modest. It is likely driven by several overlapping pathways, rather than a single direct cause.

Do Blood Pressure Medications Cause Hair Loss?

Yes. Some blood pressure medications can cause a separate form of hair shedding called telogen effluvium.

The medications most often involved are:

• Beta-blockers such as propranolol, metoprolol, atenolol, and nadolol. These are recognised in the dermatology literature as a possible cause of diffuse hair shedding, and in some cases more pronounced hair loss.
• ACE inhibitors such as lisinopril, captopril, and enalapril. These have been linked to hair loss in isolated case reports. A 2017 case report in the Journal of Pharmacy Practice described lisinopril-induced alopecia that resolved within four weeks of switching to an angiotensin receptor blocker.

Drug-related hair loss from these medications usually begins 2 to 4 months after starting the drug. It tends to present as a diffuse shedding pattern rather than patchy loss, and is often reversible once the cause is identified and managed with medical advice.

For a fuller discussion of this topic, including how shedding from these medications is diagnosed, what to do if you suspect it, and the differences between beta-blockers, ACE inhibitors, and other classes, see our dedicated article on blood pressure medications and female hair loss.

Why Is Minoxidil Used for Hair Loss If It Started as a Blood Pressure Drug?

Minoxidil is one of the better-known links between hair biology and cardiovascular pharmacology. It was first developed in the 1970s as an oral medicine for high blood pressure. It lowers blood pressure by relaxing the smooth muscle in the walls of blood vessels.

During clinical use, an unexpected side effect was observed: hypertrichosis, which is excess hair growth, particularly on the scalp and face. This led to the development of topical minoxidil formulations for hair loss.

A 2024 review in Skin Health and Disease summarised how minoxidil appears to promote hair growth. Several mechanisms are thought to be involved. These include widening of blood vessels around the follicle, activation of the Wnt/beta-catenin signalling pathway, mild anti-inflammatory effects, and possible modulation of androgen activity.

Topical minoxidil only works when an enzyme in the scalp, called sulfotransferase, converts it into its active form, minoxidil sulfate. This is one reason why response rates vary between people.

Topical minoxidil is the only medication approved by the US FDA for over-the-counter treatment of AGA, in both men and women.

What Should You Do If You Are Worried About Hair Loss and Your Heart Health?

The most important point is that hair loss alone is not enough to diagnose cardiovascular disease. Cardiovascular disease is also not reliably identified by looking at someone's scalp.

That said, the research supports two practical takeaways:

Evidence-based options exist for managing androgenetic alopecia. These range from medical therapies to minimally invasive procedures to hair transplant surgery. Suitability depends on the underlying cause, the pattern of hair loss, general health, and individual preferences, and is properly assessed during a consultation.

You can read more about the full range of hair loss treatments available in Singapore, or learn about the FUE hair transplant technique.

Frequently Asked Questions